Achieving K/DOQI laboratory target values for bone and mineral metabolism: An uphill battle

American Journal of Nephrology

Volumn 24, Issue 4, 2004, Pages 422-426

  Aly, Ziyad Al ^a   González, Esther A ^a   Martin, Kevin J ^a   Gellens, Mary E ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Chronic kidney disease; Hyperphosphatemia; Metabolic bone disease; Renal osteodystrophy; Secondary hyperparathyroidism

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PHOSPHATE;

ADULT; BONE METABOLISM; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REVIEW;

AGED; CALCIUM; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHORUS; PRACTICE GUIDELINES; RENAL DIALYSIS; RENAL OSTEODYSTROPHY; TREATMENT OUTCOME;

EID: 4644347744     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080087     Document Type: Review

References (14)

1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney DIS 1998;31:607-617.
2. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 2000;35:1226-1237.
3. Eknoyan G, Levin A, Levin NW: Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:1-201.
4. Block GA: Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients. Clin Nephrol 2000;54:318-324.
5. Levin NW, Hoenich NA: Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients. Curr Opin Nephrol Hypertens 2001;10:563-568.
6. Cannata-Andia JB, Rodriguez-Garcia M: Hyperphosphataemia as a cardiovascular risk factor - How to manage the problem. Nephrol Dial Transplant 2002;17(suppl 11):16-19.
7. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483.
8. Gallieni M, Cozzolino M, Carpani P, Zoni U, Brancaccio D: Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients. J Nephrol 2001;14:176-183.
9. Chertow GM, Burke SK, Dillon MA, Slatopolsky E: Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999;14:2907-2914.
10. 2 (Paricalcitol) safely and effectively reduces the levels of intact PTH in patients on hemodialysis. J Am Soc Nephrol 1998;9:1427-1432.
11. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-2138.
12. Kim J, Danese S, Satayathum P, Klassen P, Young EW: Achievement of proposed NKF-K/DOQI bone metabolism and disease guidelines: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003;14:269A-270A.
13. Cannata-Andia J, Diaz-Corte C: Applying the K/DOQI guidelines cut-off levels to the dialysis population: How far are we from the target? J Am Soc Nephrol 2003;14:474A.
14. Block GA, Danese M, Ofsthun N, LaBrecque J, Kim J, Lazarus JM: Association between proposed NKF-K/DOQI bone metabolism and disease guidelines and mortality risk in hemodialysis patients. J Am Soc Nephrol 2003;14:474A.